Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis

Author： Comi Giancarlo   Hartung Hans-Peter   Kurukulasuriya Nuwan C   Greenberg Steven J   Scaramozza Matthew  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.1, 2013-01, pp. : 123-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis

By Muir Victoria J.   Plosker Greg L.  

CNS Drugs, Vol. 25, Iss. 3, 2011-03 ,pp. : 239-249

Adis International

Access to resources Recommend Favorite

Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: Analysis of Economic Data from the CLARITY Study

By Ali Shehzad  

Clinical Drug Investigation, Vol. 32, Iss. 1, 2012-01 ,pp. : 15-27

Adis International

Access to resources Recommend Favorite

Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis

By Thööne Jan   Gold Ralf  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 3, 2011-03 ,pp. : 365-370

Informa Healthcare

Access to resources Recommend Favorite

Emerging oral drugs for relapsing–remitting multiple sclerosis

By Gasperini Claudio   Ruggieri Serena  

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 4, 2011-12 ,pp. : 697-712

Informa Healthcare

Access to resources Recommend Favorite

Long-Term Cost Effectiveness of Interferon- -1a in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Econometric Model

By Lepen C.  

Clinical Drug Investigation, Vol. 23, Iss. 9, 2003-01 ,pp. : 571-581

Adis International

Access to resources Recommend Favorite